Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis 2017 By ROA, Molecule type, Company & Phase - Research and Markets

Research and Markets
Posted on: 13 Dec 17

The "Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2017" report has been added to Research and Markets' offering.

The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.

As per the findings of research, it was found that most of the IPF drug candidates target chemokine receptor. The analysis was also done based on route of administration and it was found that major drug candidates are being developed to be administered by oral route.

More than 10 drug candidates received Orphan Drug Designation (ODD)

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

The drug candidate of MediciNova, Inc. has been granted Orphan Drug Designation for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF. Some of the key players developing drugs candidates for the treatment of IPF include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and others.

IPF Pipeline Analysis:

  • By route of administration
  • By molecule type
  • By company
  • By phase

Key Topics Covered:

1. Research Background

1.1. Research Objectives

1.2. Definition

1.3. Research Scope

1.4. Key Stakeholders

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

4.1. IPF Disease Overview

4.2. Key Drivers

4.3. Key Barriers

4.4. IdioPAThic Pulmonary Fibrosis Pipeline Analysis

4.5. Inactive Drug Candidates

4.6. Discontinued Drug Candidates

5. IPF Therapeutics Pipeline Analysis by Phase (2017)

5.1. Phase III: Drug Profiles

5.2. Phase II: Drug Profiles

5.3. Phase I: Drug Profiles

5.4. Pre-Clinical: Drug Profiles

5.5. Discovery: Drug Profiles

6. Clinical Trials Analysis

6.1. Clinical Trials Analysis, by Region

6.2. Clinical Trials Analysis, by Trial Status

7. Competitive Landscape

7.1. Key Players Benchmarking for IPF Therapeutics Pipeline

7.2. SWOT Analysis of IPF Therapeutics Pipeline

8. Company Profiles

8.1. Companies having Pipeline of IPF Therapeutics

9. Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 13/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.